Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins

Author:

Ray Kausik K.1,Stoekenbroek Robert M.2,Kallend David3,Leiter Lawrence A.4,Landmesser Ulf5,Wright R. Scott6,Wijngaard Peter3,Kastelein John J.P.2

Affiliation:

1. Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, UK (K.K.R.).

2. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, the Netherlands (R.M.S., J.J.P.K.).

3. The Medicines Company, Parsippany, NJ (D.K., P.W.).

4. Division of Endocrinology and Metabolism, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, University of Toronto, Canada (L.A.L.).

5. Department of Cardiology, Charité–Universitätsmedizin Berlin, Berlin Institute of Health and German Center for Cardiovascular Research, Partner Site Berlin, Germany (U.L.).

6. Department of Cardiology, Mayo Clinic, Rochester, MN (R.S.W.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference39 articles.

1. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

2. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

3. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration [published online ahead of print August 14, 2017].;Ference BA;Eur Heart J

4. Paper presented at: American College of Cardiology Annual Meeting Orlando FL March 10–12 2018 Paper presented at: American College of Cardiology Annual Meeting PG Steg ODYSSEY OUTCOMES Investigators and Committees ODYSSEY Outcomes: CV outcomes with alirocumab after ACS.

5. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Cited by 137 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3